Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down before the market opened on Thursday . The stock had previously closed at $33.55, but opened at $31.71. Nanobiotix shares last traded at $32.2510, with a volume of 8,028 shares trading hands.

Analyst Upgrades and Downgrades

NBTX has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Leerink Partners lifted their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. UBS Group lifted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Finally, Guggenheim lifted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Nanobiotix currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Price Performance

The stock has a 50 day moving average of $37.51 and a two-hundred day moving average of $29.26.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million during the quarter. As a group, analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors have recently bought and sold shares of NBTX. Millennium Management LLC purchased a new position in Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP purchased a new position in Nanobiotix during the 4th quarter valued at about $220,000. Optiver Holding B.V. purchased a new position in Nanobiotix during the 3rd quarter valued at about $101,000. Finally, Royal Bank of Canada grew its stake in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.